⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 20, 2013JAMAOpen Access

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

clinicaltrials.gov Identifier: NCT00334828.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Opal et al. (2013) studied this question.

synapsesocial.com/papers/69d5721c75589c71d767e4e9 https://doi.org/10.1001/jama.2013.2194

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4Original Research · 1999 · 2,218 citations
2Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant<i>Escherichia coli</i>Randomized Controlled Trial · 1982 · 1,052 citations
3Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy VolunteersRCT · 2004 · 73 citations
4Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic ShockPrognostic Study · 1999 · 617 citations
5Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal TransductionOriginal Research · 1999 · 1,975 citations